Eli Lilly and Company (LLY)
NYSE: LLY · Real-Time Price · USD
845.72
+2.09 (0.25%)
At close: Oct 8, 2025, 4:00 PM EDT
844.68
-1.04 (-0.12%)
After-hours: Oct 8, 2025, 4:08 PM EDT
Eli Lilly Revenue
Eli Lilly had revenue of $15.56B in the quarter ending June 30, 2025, with 37.64% growth. This brings the company's revenue in the last twelve months to $53.26B, up 36.83% year-over-year. In the year 2024, Eli Lilly had annual revenue of $45.04B with 32.00% growth.
Revenue (ttm)
$53.26B
Revenue Growth
+36.83%
P/S Ratio
14.25
Revenue / Employee
$1,133,151
Employees
47,000
Market Cap
759.23B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 45.04B | 10.92B | 32.00% |
Dec 31, 2023 | 34.12B | 5.58B | 19.56% |
Dec 31, 2022 | 28.54B | 223.00M | 0.79% |
Dec 31, 2021 | 28.32B | 3.78B | 15.40% |
Dec 31, 2020 | 24.54B | 2.22B | 9.95% |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 422.82B |
Johnson & Johnson | 90.63B |
Merck & Co. | 63.62B |
AbbVie | 58.33B |
AstraZeneca | 56.50B |
Novartis AG | 55.19B |
Novo Nordisk | 49.11B |
Thermo Fisher Scientific | 43.21B |
LLY News
- 8 hours ago - HealthTap joins Lilly's online platform to offer diabetes management services - Reuters
- 1 day ago - Former FDA vaccine chief Peter Marks joins Eli Lilly, STAT reports - Reuters
- 1 day ago - Lilly's Omvoh (mirikizumab-mrkz) is the first and only IL-23p19 antagonist to show four years of sustained, corticosteroid-free comprehensive patient outcomes in ulcerative colitis - PRNewsWire
- 2 days ago - My Top 5 Biotech Stocks Big Pharma Could Buy Next - Seeking Alpha
- 2 days ago - Eli Lilly to invest over $1 billion in India to expand manufacturing capacity - Reuters
- 5 days ago - Pharmaceutical Stocks: Valuations And Pipelines Are Only Beginning To Be Appreciated - Seeking Alpha
- 5 days ago - Top 50 High-Quality Dividend Growth Stocks For October 2025 - Seeking Alpha
- 5 days ago - Kernal Bio Joins Lilly Gateway Labs to Accelerate In Vivo Cell Therapies - Business Wire